Matthew Herder

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Decision Making

Respiratory Syndrome Coronavirus

Drug Administration

Cognitive Decline

Top Venues

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics

International journal of health policy and management

Clinical trials (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Matthew Herder
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 51 (4) (2024)
Matthew Herder
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 51 (4) (2024)
Matthew Herder
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 51 (4) (2024)
Quinn Grundy, Chantal Campbell, Ridwaanah Ali, Matthew Herder, Kelly Holloway
"A Most Equitable Drug": How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 52 (1) (2024)
Matthew Herder
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 51 (4) (2024)
Matthew Herder
Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 51 (4) (2024)
Ipek Eren Vural, Matthew Herder, Agnieszka Doll, Janice E Graham
Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic. International journal of health policy and management 12 (2023)
Jessie Pappin, Itai Bavli, Matthew Herder
On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data. Clinical trials (London, England) 19 (5) (2022)